Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Nebula Research & Development LLC

Nebula Research & Development LLC decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 43.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,670 shares of the company’s stock after selling 2,035 shares during the quarter. Nebula Research & Development LLC’s holdings in Krystal Biotech were worth $418,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Krystal Biotech during the fourth quarter worth approximately $34,391,000. Raymond James Financial Inc. acquired a new position in Krystal Biotech during the 4th quarter worth $15,989,000. Price T Rowe Associates Inc. MD increased its position in shares of Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock worth $79,812,000 after purchasing an additional 71,200 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares in the last quarter. Finally, TimesSquare Capital Management LLC raised its stake in Krystal Biotech by 39.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after buying an additional 44,646 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent research reports. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Finally, HC Wainwright upped their price objective on Krystal Biotech from $221.00 to $240.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus price target of $222.71.

Krystal Biotech Trading Up 0.5 %

NASDAQ KRYS opened at $170.57 on Wednesday. The company has a market capitalization of $4.93 billion, a PE ratio of 57.05 and a beta of 0.75. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The firm’s fifty day simple moving average is $176.00 and its 200-day simple moving average is $171.49.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. During the same period in the previous year, the company earned $0.30 earnings per share. The company’s revenue was up 116.4% compared to the same quarter last year. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).